Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
3,016
Period ended Dec 31, 2025
Change on a year earlier
+35.7%
2,222 in FY2024
History
11 years
Since FY2015
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,016 | +35.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 2,222 | +35.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,635 | +26.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 1,296 | +16.0% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,117 | +25.9% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 887 | +34.2% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 661 | +20.2% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 550 | +72.4% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 319 | +126.2% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 141 | +1,310.0% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 10 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up repatha (evolocumab — pcsk9 inhibitor, cardiovascular) — worldwide product sales ($m)
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M)1,663 · FY2025
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Rest of World (ROW) product sales ($M)1,353 · FY2025
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide reported sales growth YoY (%)36.0% · FY2025
- Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%)43.0% · FY2024
Cite this data
StockData. (2026). Amgen Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_repatha_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.